Descripción del proyecto
Solución exhaustiva sin contacto para monitorizar la apnea del sueño
Más del 30 % de la población mundial padece distintos tipos de trastornos del sueño. La apnea del sueño es un trastorno del sueño grave en que la respiración de una persona se ve interrumpida mientras duerme. La apnea del sueño no tratada aumenta el riesgo de paro cardíaco repentino, accidente cerebrovascular y mortalidad cardiovascular. La plataforma innovadora recientemente desarrollada es fácil de usar y se basa en una solución centrada en el paciente con «software» avanzado e ingeniería de «hardware». En contraste con el método actual, la tecnología sin contacto desarrollada permite a los profesionales sanitarios evaluar a los pacientes a fin de detectar la apnea del sueño en su entorno y comportamiento de sueño más naturales. El proyecto financiado con fondos europeos Sleepiz pretende validar la viabilidad comercial de la plataforma, lo que incluye el análisis de mercado, la evaluación comparativa coste-beneficio y el acercamiento a las partes interesadas.
Objetivo
Sleep loss is an aggravating factor in the global burden of disease with collateral effects on cardiovascular and mental health as well as injury and death through human error.
State of the art clinical diagnostic tools that measure sleep data are expensive, complex to interpret, and stressful for the patients. Today’s most accurate diagnostic tools require patients to strap electrodes and chest monitors to their body and undergo overnight testing, often in a clinic.
Sleepiz AG has developed a breakthrough solution in clinical sleep-monitoring solutions. Our innovation, Sleepiz, is a contact-free sensor-based diagnostic device for sleep specialists and clinics. It can analyze patients’ vital signs and environmental measurements without touching the patient. We use test results to continuously feed and improve our self-learning algorithms.
Sleep specialists will prescribe Sleepiz to patients to use in their homes. Doctors can view the results remotely and in real-time. We will charge clinics a fee per session in line with today’s diagnostic costs; our solution will be up to 2x more time- and cost-efficient.
The approval of Sleepiz as a clinical diagnostic device in the EU and US, together with the ramp-up of commercial activities and stakeholder outreach, comprise the major objectives of this project.
The goal of phase 1 is to further validate product-market fits, along with planning and allocating resources for clinical validation trials during phase 2.
Sleepiz AG is a Swiss startup comprised of young entrepreneurs and innovators. We have already created great interest: 4 hospitals that use clinical-grade sleep diagnosis tools - a market worth close to €5Bn – want to validate our system. An advisory board of leading experts in related tech and innovation fields will help guide our go-to-market plan.
We project annual sales revenues of €34.16M by year 5 after market launch, and we forecast directly creating 197 jobs.
Ámbito científico
- medical and health sciencesclinical medicinepsychiatrysleep disorders
- natural sciencescomputer and information sciencesdata science
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicineneurologydementia
- medical and health sciencesbasic medicineneurologystroke
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
8008 ZURICH
Suiza
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.